store at low temperature
store at -80°C
Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody targeting CD2. Siplizumab selectively depletes effector memory T cells and promotes relative expansion of alloreactive regulatory T cells in vitro. Siplizumab can be used to treat plaque psoriasis.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 222.00 | |
5 mg | In stock | $ 647.00 | |
10 mg | In stock | $ 987.00 |
Description | Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody targeting CD2. Siplizumab selectively depletes effector memory T cells and promotes relative expansion of alloreactive regulatory T cells in vitro. Siplizumab can be used to treat plaque psoriasis. |
In vitro |
Siplizumab (MEDI-507; 0.00001-10 nM) binds to FcγR and induces signal transduction[1]. Siplizumab (0.0001-10 μg/mL) mediates cell depletion and reduces T-cell proliferation[1]. |
Synonyms | MEDI-507 |
Molecular Weight | N/A |
CAS No. | 288392-69-8 |
store at low temperature
store at -80°C
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Siplizumab 288392-69-8 Others MEDI 507 MEDI-507 MEDI507 inhibitor inhibit